Home > Oceania > New Zealand > New Zealand Healthcare Professional

This website is intended for New Zealand Healthcare Professionals only.

Each capsule contains 200 mg molnupiravir
Each bottle contains 40 capsules
Store below 30ºC
Lagevrio is fully funded if the patient meets the Access Criteria for oral antiviral COVID-19 treatment (as per Pharmac’s website) and the prescriber has endorsed the prescription. The supply of treatment is via Pharmac’s approved distribution process. Lagevrio can also be purchased privately, and a charge will apply1.

Have a question about an MSD Product or want to report an Adverse Event or Quality Issue?

Phone: 0800 500 673
Monday – Friday 9:30 a.m. – 5:30 p.m. Australian Eastern Daylight Time

Email: dpoc.australia@msd.com

MSD New Zealand Address

Merck Sharp & Dohme (New Zealand) Limited. Level 3, 123 Carlton Gore Road, Newmarket, Auckland

Lagevrio is a Prescription Medicine. Please review the Lagevrio Data Sheet before prescribing. The Data Sheet is available at www.medsafe.govt.nz.

INDICATION: Provisional consent for the treatment of mild to moderate COVID-19 in adults (≥18 years) who are at increased risk of progressing to severe COVID-19, hospitalisation or death.

CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients.

PRECAUTIONS: Use in pregnancy is not recommended; consider the need for a pregnancy test before initiating treatment in women of childbearing potential who are sexually active. It is recommended that sexually active women of childbearing potential use contraception during and for 4 days after the last dose, and that men who are sexually active with a partner of childbearing potential use an adequate form of contraception during and for 3 months after treatment. Breastfeeding is not recommended during treatment and for 4 days after the last dose. Not recommended in paediatric patients. Hypersensitivity reactions have been reported; if signs and symptoms of a clinically significant hypersensitivity reaction occur, immediately discontinue Lagevrio and initiate appropriate medications and/or supportive care.

ADVERSE EVENTS: Common: diarrhoea, nausea, dizziness. The following have been reported in post-marketing experience: hypersensitivity, angioedema, erythema, rash, urticaria. Based on Data Sheet dated 14 April 2022.

Reference: 1. Pharmac. Pharmaceutical Schedule. Available at: https://schedule.pharmac.govt.nz/ScheduleOnline.php. Accessed on: 26 Apr 2022.

Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

NZ-LAG-00031 First issued June 22 TAPS DA 2208KN.